Inhaled tigecycline is effective against Mycobacterium abscessus in vitro and in vivo
Open Access
- 15 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 75 (7) , 1889-1894
Abstract
Mycobacterium abscessus causes chronic pulmonary infections. Owing to its resistance to most classes of antibiotics, treatment is complex and cure rates are only 45%. Tigecycline is active against M. abscessus, but severe toxicity and the need for IV administration limit its use. To assess the potential of inhaled tigecycline as a treatment for M. abscessus pulmonary disease, by measuring its efficacy in a mouse model of chronic M. abscessus pulmonary disease, establishing the intracellular activity of tigecycline against M. abscessus in human macrophages and measuring the activity of tigecycline in the sputum of cystic fibrosis patients. We infected GM-CSF knockout mice with M. abscessus by intrapulmonary aerosol. Infected mice were treated with tigecycline in 0.25, 1.25 and 2.5 mg doses, by inhalation, or untreated, for 28 days. Tigecycline was added to human peripheral blood-derived macrophages infected with M. abscessus to assess its intracellular activity. We performed a time–kill kinetics experiment of tigecycline against M. abscessus with and without sputum of cystic fibrosis patients. Inhaled tigecycline proved highly effective against M. abscessus in GM-CSF knockout mice. The effect was dose dependent. Tigecycline showed potent activity against M. abscessus in macrophages and retained most of its activity in the presence of sputum of cystic fibrosis patients. Inhaled tigecycline may represent a viable treatment option for M. abscessus pulmonary disease, where treatment outcomes are currently very poor. A stable and safe formulation is required to proceed to further pharmacodynamic studies and ultimately clinical trials.Keywords
Funding Information
- Netherlands Organization for Scientific Research
- NWO
- ZonMw (Veni 016.176.024)
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (R01AI120670)
- NIH
This publication has 21 references indexed in Scilit:
- Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary DiseaseAntimicrobial Agents and Chemotherapy, 2016
- Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease ModelAntimicrobial Agents and Chemotherapy, 2016
- US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosisThorax, 2015
- A Novel Formulation of Tigecycline Has Enhanced Stability and Sustained Antibacterial and Antileukemic ActivityPLOS ONE, 2014
- Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infectionsJournal of Antimicrobial Chemotherapy, 2014
- Airway-Specific Inducible Transgene Expression Using Aerosolized DoxycyclineAmerican Journal of Respiratory Cell and Molecular Biology, 2013
- GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against Mycobacterium abscessusJournal of Antimicrobial Chemotherapy, 2013
- Mycobacterium abscessus: a new antibiotic nightmareJournal of Antimicrobial Chemotherapy, 2012
- In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2010
- Comparison of the In Vitro Activity of the Glycylcycline Tigecycline (Formerly GAR-936) with Those of Tetracycline, Minocycline, and Doxycycline against Isolates of Nontuberculous MycobacteriaAntimicrobial Agents and Chemotherapy, 2002